PGEN vs RGNX
PGEN: Gene therapy precision medicine company with FDA-approved adenoviral immunotherapy for HPV-driven respiratory disease and a development pipeline of CAR-T and viral vector candidates across oncology and infectious disease. RGNX: Clinical-stage gene therapy company using proprietary NAV vectors to deliver functional genes for rare genetic and retinal disorders through partnerships with major pharma.
Side-by-side fundamentals
| Metric | PGEN | RGNX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.32 | $10.20 | |
| Market cap as of 2026-07-23 | $1.9B | $529M | |
| PEG as of 2026-07-23 | -0.04 | -0.02 | PGEN lower |
| Net margin as of 2026-07-23 | -647.0% | -330.2% | RGNX higher |
| Gross margin as of 2026-07-23 | +80.1% | +68.2% | PGEN higher |
| Operating margin as of 2026-07-23 | -297.2% | -292.3% | RGNX higher |
| ROE as of 2026-07-23 | -642.5% | -232.5% | RGNX higher |
| ROA as of 2026-07-23 | -144.1% | -61.0% | RGNX higher |
| Debt / equity as of 2026-07-23 | 4.62 | 8.41 | PGEN lower |
| Revenue growth (YoY) as of 2026-07-23 | +652.1% | -44.0% | PGEN higher |
| Revenue CAGR (3y) SEC XBRL | -28.9% | +14.8% | RGNX higher |
| Beta as of 2026-07-23 | 1.06 | 0.91 | |
| 1-year return as of 2026-07-22 close | +250.0% | +19.0% | PGEN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.